• Home
  • Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)

Author List
Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/326248139
Publication Year
2022
Publication Title
Aggarwal, R.R., Vuky, J., VanderWeele, D.J., Rettig, M., Heath, E.I., Beer, T.M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., Liu, B., Nasoff, M., Dorr, A., Small, E.J.. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022; (40):16_s3001.